Ataraxis develops artificial intelligence methods to integrate multi-modal data for cancer prognosis and treatment selection, addressing previously unsolvable problems in cancer care.

Ataraxis

Ataraxis AI | 1,052 followers on LinkedIn. Transforming Cancer Care with AI Precision Medicine | Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. 

Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays.

CSR at ataraxis

naomi gomez

CEO & Founder at Ataraxis AI

Jan Witowski MD PhD

Machine Learning Engineer at Stealth AI Startup | MSc Data Science Candidate at NYU

Ken Zeng

Student at NYU Tandon School of Engineering

Michael Bian

Ataraxis AI

Today, we are launching Ataraxis AI to fulfill the promise of precision medicine. At Ataraxis, we are pioneering a new era of AI-native diagnostic tests that answer questions about patient outcomes and treatment response with greater accuracy, faster turnaround times, and broader applicability than molecular tests. Our first product, Ataraxis Breast, is the world's first AI-native prognostic/predictive test for breast cancer. Validated in a study of 8,161 patients across 15 cohorts from seven countries, this landmark study demonstrated that Ataraxis Breast: 📌 Delivers up to 30% higher accuracy than standard-of-care molecular diagnostics 📌 Works across all breast cancer subtypes, expanding testing to 100,000 more patients each year 📌 Is faster, more cost-effective, and capable of addressing new clinical questions Ataraxis Breast is powered by Kestrel, our state-of-the-art AI foundation model for digital pathology. Kestrel is a pan-cancer model that provides new insights into cancer, enabling predictions for patient and treatment outcomes in breast cancer and beyond. Developed using the latest AI methodologies—including self-supervised learning and vision transformers—Kestrel was created with guidance from our special advisor, Yann LeCun . Last year, we raised $4M in a round co-led by Giant Ventures and Obvious Ventures . Thank you to our investors, team, and supporters. Learn more about today's announcement here: https://lnkd.in/embW5s7g . #AI #PrecisionMedicine #CancerDiagnostics #BreastCancer #CancerCare

“The entire mission of our company is to start providing information and answers to questions where there was no alternative.” Today in Forbes, Alex Knapp covers our founding story, our first product, and our mission to create tests that predict patient outcomes and personalize treatments for at least 50% of the 26 million new cancer patients expected to be diagnosed globally by 2030.

Metric
Company Name	Ataraxis
Symbol
MSH ID	AI:ATARAXIS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Technology
Country	US
Stage
Employee Count
Website	ataraxis.ai
LinkedIn	ataraxis-ai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ATAR

AI:ATARAXIS

Ataraxis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue